Label: METHOCARBAMOL- methocarbamol tablets tablet, coated
-
NDC Code(s):
70518-1738-0,
70518-1738-1,
70518-1738-2,
70518-1738-3, view more70518-1738-4, 70518-1738-5, 70518-1738-6, 70518-1738-7, 70518-1738-8
- Packager: REMEDYREPACK INC.
- This is a repackaged label.
- Source NDC Code(s): 70010-770
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
Drug Label Information
Updated February 22, 2024
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
-
DESCRIPTION
Methocarbamol tablet, USP, a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.
The chemical name of methocarbamol is 1,2-Propanediol,3-(2-methoxyphenoxy)-,1-Carbamate,(±)-.(or) (±)-3-(o-Methoxyphenoxy)-1,2-Propanediol 1-carbamate and has the empirical formula C 11H 15NO 5. Its molecular weight is 241.24g/mol. The structural formula is shown below.
Methocarbamol is a white powder, sparingly soluble in water and in chloroform, soluble in alcohol (only with heating), insoluble in benzene and in n-hexane.
Methocarbamol tablets, USP are available as 500 mg and 750 mg tablets for oral administration.
Methocarbamol tablets, USP 500 mg are light orange colored, round shaped film coated tablets debossed with "G" above the score line on one side and "500" on other side.
Methocarbamol tablets, USP 750 mg are light orange colored, caplet shaped film coated tablets debossed with "G" on one side and "750" on other side.
Methocarbamol tablets, USP 500 mg and 750 mg contain the following inactive ingredients: colloidal silicon dioxide, maize starch, povidone, sodium lauryl sulfate, sodium starch glycolate, and stearic acid.
The tabets are coated with Aquarius Prime which contains FD&C yellow 6, hydroxypropylcellulose, hypromellose, polysorbate 80, propylene glycol, and titanium dioxide
-
CLINICAL PHARMACOLOGY
The mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.
Pharmacokinetics
In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.
Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely. Essentially all methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged methocarbamol also are excreted in the urine.
Special Populations
Elderly
The mean (± SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean (± SD) age, 69 (± 4) years) was slightly prolonged compared to a younger (mean (± SD) age, 53.3 (± 8.8) years), healthy population (1.5 (± 0.4) hours versus 1.1 (± 0.27) hours, respectively). The fraction of bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41 to 43% versus 46 to 50%, respectively).Renally impaired
The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean (± SD) elimination half-life in these two groups was similar: 1.2 (± 0.6) versus 1.1 (±0.3) hours, respectively.Hepatically impaired
In 8 patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to that obtained in 8 age- and weight-matched normal subjects. The mean (± SD) elimination half-life in the cirrhotic patients and the normal subjects was 3.38 (± 1.62) hours and 1.11 (± 0.27) hours, respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% compared to 46 to 50% in the normal subjects.
-
INDICATIONS AND USAGE
Methocarbamol tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.
- CONTRAINDICATIONS
-
WARNINGS
Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol tablets should be cautioned about combined effects with alcohol and other CNS depressants.
Safe use of Methocarbamol tablets has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, Methocarbamol tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see PRECAUTIONS, Pregnancy ).
Use in Activities Requiring Mental Alertness
Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.
-
PRECAUTIONS
INFORMATION FOR PATIENTS
Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.
Repackaged By / Distributed By: RemedyRepack Inc.
625 Kolter Drive, Indiana, PA 15701
(724) 465-8762
DRUG INTERACTIONS
See WARNINGS and PRECAUTIONS for interaction with CNS drugs and alcohol.
Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.
DRUG/LABORATORY TEST INTERACTIONS
Methocarbamol may cause color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY
Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.
PREGNANCY
Teratogenic Effects
Pregnancy Category C
Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol tablets should be given to a pregnant woman only if clearly needed.Safe use of methocarbamol tablet has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, Methocarbamol tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see WARNINGS).
NURSING MOTHERS
Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when methocarbamol tablets are administered to a nursing woman.
-
ADVERSE REACTIONS
Adverse reactions reported coincident with the administration of methocarbamol include:
Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache
Cardiovascular system: Bradycardia, flushing, hypotension, syncope, thrombophlebitis
Digestive system: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting
Hemic and lymphatic system: Leukopenia
Immune system: Hypersensitivity reactions
Nervous system: Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures(including grand mal), vertigo
Skin and special senses: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, Urticaria
To report SUSPECTED ADVERSE REACTIONS, contact Granules USA, Inc. at 1-877-770-3183 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
-
OVERDOSAGE
Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma.
In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.
Treatment
Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.
-
DOSAGE AND ADMINISTRATION
Methocarbamol Tablets, USP 500 mg – Adults:
Initial dosage: 3 tablets 4 times daily
Maintenance dosage: 2 tablets 4 times daily
Methocarbamol Tablets, USP 750 mg – Adults:
Initial dosage: 2 tablets 4 times daily
Maintenance dosage: 1 tablet every 4 hours or 2 tablets 3 times daily
Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.
-
HOW SUPPLIED
Methocarbamol tablets, USP 750 mg are light orange colored, caplet shaped film coated tablets debossed with "G" on one side and"750" on other side.
NDC: 70518-1738-00
NDC: 70518-1738-01
NDC: 70518-1738-02
NDC: 70518-1738-03
NDC: 70518-1738-04
NDC: 70518-1738-05
NDC: 70518-1738-06
NDC: 70518-1738-07
NDC: 70518-1738-08
PACKAGING: 30 in 1 BLISTER PACK
PACKAGING: 120 in 1 BOTTLE PLASTIC
PACKAGING: 100 in 1 BOTTLE PLASTIC
PACKAGING: 60 in 1 BOTTLE PLASTIC
PACKAGING: 30 in 1 BLISTER PACK
PACKAGING: 20 in 1 BOTTLE PLASTIC
PACKAGING: 60 in 1 BOTTLE PLASTIC
PACKAGING: 90 in 1 BOTTLE PLASTIC
PACKAGING: 30 in 1 BOTTLE PLASTIC
Store between 20ºC and 25ºC (68ºF and 77º F)
[see USP Controlled Room Temperature].
Dispense in tight container.
Repackaged and Distributed By:
Remedy Repack, Inc.
625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762
-
PRINCIPAL DISPLAY PANEL
DRUG: Methocarbamol
GENERIC: Methocarbamol Tablets
DOSAGE: TABLET, COATED
ADMINSTRATION: ORAL
NDC: 70518-1738-0
NDC: 70518-1738-1
NDC: 70518-1738-2
NDC: 70518-1738-3
NDC: 70518-1738-4
NDC: 70518-1738-5
NDC: 70518-1738-6
NDC: 70518-1738-7
NDC: 70518-1738-8
COLOR: orange
SHAPE: CAPSULE
SCORE: No score
SIZE: 19 mm
IMPRINT: G;750
PACKAGING: 30 in 1 BLISTER PACK
PACKAGING: 120 in 1 BOTTLE PLASTIC
PACKAGING: 100 in 1 BOTTLE PLASTIC
PACKAGING: 60 in 1 BOTTLE PLASTIC
PACKAGING: 30 in 1 BLISTER PACK
PACKAGING: 20 in 1 BOTTLE PLASTIC
PACKAGING: 60 in 1 BOTTLE PLASTIC
PACKAGING: 90 in 1 BOTTLE PLASTIC
PACKAGING: 30 in 1 BOTTLE PLASTIC
ACTIVE INGREDIENT(S):
- METHOCARBAMOL 750mg in 1
INACTIVE INGREDIENT(S):
- SILICON DIOXIDE
- STARCH, CORN
- POVIDONE
- SODIUM LAURYL SULFATE
- SODIUM STARCH GLYCOLATE TYPE A POTATO
- STEARIC ACID
- FD&C YELLOW NO. 6
- HYDROXYPROPYL CELLULOSE
- HYPROMELLOSE 2910 (6 MPA.S)
- POLYSORBATE 80
- PROPYLENE GLYCOL
- TITANIUM DIOXIDE
-
INGREDIENTS AND APPEARANCE
METHOCARBAMOL
methocarbamol tablets tablet, coatedProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:70518-1738(NDC:70010-770) Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength METHOCARBAMOL (UNII: 125OD7737X) (METHOCARBAMOL - UNII:125OD7737X) METHOCARBAMOL 750 mg Inactive Ingredients Ingredient Name Strength STARCH, CORN (UNII: O8232NY3SJ) POVIDONE (UNII: FZ989GH94E) SILICON DIOXIDE (UNII: ETJ7Z6XBU4) SODIUM LAURYL SULFATE (UNII: 368GB5141J) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) STEARIC ACID (UNII: 4ELV7Z65AP) FD&C YELLOW NO. 6 (UNII: H77VEI93A8) HYDROXYPROPYL CELLULOSE (UNII: RFW2ET671P) HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6) POLYSORBATE 80 (UNII: 6OZP39ZG8H) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) TITANIUM DIOXIDE (UNII: 15FIX9V2JP) Product Characteristics Color orange Score no score Shape CAPSULE Size 19mm Flavor Imprint Code G;750 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:70518-1738-0 30 in 1 BLISTER PACK; Type 0: Not a Combination Product 12/17/2018 08/11/2020 2 NDC:70518-1738-1 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 07/31/2020 08/21/2020 3 NDC:70518-1738-2 100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 09/02/2020 09/03/2020 4 NDC:70518-1738-3 60 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 09/03/2020 10/12/2020 5 NDC:70518-1738-4 30 in 1 BLISTER PACK; Type 0: Not a Combination Product 04/29/2022 6 NDC:70518-1738-5 20 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 05/24/2022 7 NDC:70518-1738-6 60 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 06/22/2022 8 NDC:70518-1738-7 90 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 08/16/2022 9 NDC:70518-1738-8 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 01/11/2023 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA209312 12/17/2018 Labeler - REMEDYREPACK INC. (829572556)